Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A trial of a new inhaled antiviral drug for COVID-19 has shown positive results and the drug is now moving into a larger international phase 3 trial of hospitalised patients.

Digital illustration of a human with a transparent body and model of coloured lungs inside with coronavirus particle models.

A new treatment, a protein called interferon beta or SNG001, has been developed with results from the phase 2 trial published in the Lancet Respiratory Medicine journal. The study showed that hospitalised COVID-19 patients on nebulised interferon bets recovered quicker and that the drug was safe.

Interferon beta, produced naturally by the body when it gets a viral infection, is inhaled directly into the lungs of patients with coronavirus using a nebuliser, with the aim of reducing viral load and stimulating an immune response. Oxford University Hospitals contributed 10% of the patients in the phase 2 trial.

The large phase 3 trial, which is expected to involve 900 participants and take place in up to 20 NHS sites, has been deemed an urgent public health research study by the Department of Health and Social Care, and will be prioritised for set-up and delivery across the NHS by the NIHR Clinical Research Network over the coming months.

The full story is available on the NIHR Oxford Biomedical Research Centre website

The story is also featured on the MRC Weatherall Institute of Molecular Medicine website

Similar stories

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Oxford University and partners win government funding to evaluate Paige Prostate Cancer Detection System

A prostate cancer detection software system to help pathologists quickly identify suspicious areas of tissue, developed by Paige, will be investigated in a multicentre clinical study led by Oxford University as part of a successful NHSx Artificial Intelligence Health and Care Award application.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.